Bionano Genomics Announces the Final Speaker Lineup for 2022 Symposium
January 07 2022 - 8:00AM
Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping
(OGM) solutions on the Saphyr® system and provider of the leading
software solutions for visualization, interpretation and reporting
of genomic data, today announced its Symposium lineup of 31 oral
presentations delivered from 27 different customers worldwide
featuring the utility of OGM across a wide range of applications
for genetic disease and cancer research. In all, 45% of the
customer presentations at Symposium are from North America while
55% are from Europe. Symposium will take place virtually from
January 10 to 13, 2022. During these four days, customers will
showcase their latest research findings using OGM in constitutional
cytogenomics, hematologic malignancies, solid tumors and in
combination with next-generation sequencing (NGS). Each day will
feature oral customer presentations, a live panel with Q&A and
a scientific poster exhibit within the virtual exhibition
hall.
“We believe Symposium is the quintessential event for the OGM
community to come together and share the progress they are making
and their ideas for expanding the utility of OGM,” said Erik
Holmlin, PhD, President and CEO of Bionano Genomics. “Last year we
were impressed by the utility, scope and breath of applications
presented by our customers using the Saphyr system. Symposium is an
opportunity for anyone interested or currently working with OGM to
form connections within the community and see the potential impact
of looking at the genome in a different way. Bionano is dedicated
to elevating human health by transforming the way the world sees
the genome and I’m greatly looking forward to seeing our customers
showcase their accomplishments with OGM at Symposium. We also plan
on conducting a Symposium in China later this year to bring
together our Asia Pacific customers to feature their
accomplishments using OGM.”
“Symposium in 2021 marked a historic event where OGM users
showcased their data. Since then, we have made significant
improvements in OGM workflow and data analysis which have allowed
our customers around the world to advance their clinical and
translational research. We have seen the implementation of our
Saphyr system across a broad range of clinical research
applications for consolidating traditional cytogenetics workflows
to OGM as well as demonstrating its utility in combination with
NGS,” said Alka Chaubey, PhD, FACMG, Chief Medical Officer at
Bionano. “Symposium attendees have an opportunity to learn from
their peers and we will continue to provide our customers with the
training, education and services to support our goal of making OGM
the standard of care.”
Each session of Symposium will start at 8:00 am PST and will
last approximately 5 hours. After the scientific presentations, the
speakers will join for a live panel discussion and Q&A
moderated by Dr. Chaubey. In addition, each day will feature a
scientific poster exhibit. Below is the list of customer
presentations per day and application area.
January 10: Constitutional Cytogenomics |
|
|
Speaker Name |
Institution |
State / Country |
Talk Title |
Chaim Jalas |
The Foundation for Embryonic Competence |
New Jersey, USA |
Validation of Optical Genome Mapping for Preimplantation Genetic
Analysis – Structural Rearrangement (PGD-SR) Applications |
Dr. Laila El-Khattabi |
Assistance Publique–Hôpitaux de Paris (AP-HP) - Université de
Paris |
Paris, France |
Balanced Translocations Associated with Male Infertility: How
Optical Genome Mapping Could Lead to New Discoveries? |
Dr. Shirley Heggarty |
Belfast Health and Social Care Trust |
Belfast, UK |
Clinical Utility of Optical Genome Mapping in a Constitutional
Cytogenetics Laboratory |
Dr. Alexander Hoischen |
Radboud University Medical Center |
Nijmegen, Netherlands |
Optical Genome Mapping: Mapping Difficult Structural Variant Types
- Repeat Expansions |
Dr. Anwar Iqbal |
University of Rochester Medical Center |
New York, USA |
Validation Study of Optical Genome Mapping for Postnatal and
Prenatal Clinical Research According to Established NYSDOH
Guidelines |
Dr. Nikhil Sahajpal |
Augusta University |
Georgia, USA |
Enhanced Structural Variation Detection with OGM in Constitutional
Disorders |
January 11: Hematologic Malignancies |
|
|
Speaker Name |
Institution |
State / Country |
Talk Title |
Bence Dvorak |
University Children's Hospital Zurich- Eleonore Foundation |
Zurich, Switzerland |
Characterization of Plasma Cell Dyscrasias (PCD) by Optical Genome
Mapping |
Dr. Jonathan L. Lühmann |
Hannover Medical School |
Hannover, Germany |
The Clinical Utility of Optical Genome Mapping for the Assessment
of Genomic Aberrations in Acute Lymphoblastic Leukemia |
Dr. Anna Puiggros |
Hospital del Mar |
Barcelona, Spain |
The Hidden Side of Genomic Complexity: Learning from OGM in Chronic
Lymphocytic Leukemia |
Dr. Barbara Dewaele |
University Hospitals Leuven |
Leuven, Belgium |
Opportunities of Optical Genome Mapping for Genetic Diagnosis in
Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia |
Dr. Kornelia Neveling |
Radboud University Medical Center |
Nijmegen, Netherlands |
Technical and Clinical Validation of Optical Genome Mapping |
Dr. Elena García Sánchez |
Hospital Infantil Universitario Niño Jesús |
Madrid, Spain |
Optical Genome Mapping for Diagnosis of Paediatric Leukaemia |
Dr. Brynn Levy |
Columbia University Medical Center |
New York, USA |
Assessing Genomic Aberrations in AML using Optical Genome Mapping:
Insights from a National Multi-Center Study |
Dr. Adrian Dubuc |
Harvard Medical School Brigham and Women's Hospital |
Massachusetts, USA |
Shining a New Light on Cancer Cytogenetics: Leveraging Novel
Technological Approaches for Improved Understanding in B-ALL |
Dr. Adam C. Smith |
Laboratory Medicine Program, University Health Network, University
of Toronto |
Toronto, Canada |
A Year in Review: Parallel Testing of Hematologic Malignancies
Using Optical Genome Mapping Compared to Conventional
Cytogenetics |
Dr. Saurabh Gupta |
Quest Diagnostics |
New Jersey, USA |
Optical genome mapping: Utility for stratification of B-CLL by
accurate identification of clinically relevant structural
variants |
January 12: Solid Tumors |
|
|
Speaker Name |
Institution |
|
Talk Title |
Dr. Elena García Sánchez |
Hospital Infantil Universitario Niño Jesús |
Madrid, Spain |
Optical Genome Mapping: Application for Analysis of
Non-Haematological Cancers |
Dr. Tuomo Mantere |
University of Oulu, Finland |
Oulu, Finland |
Optical Genome Mapping in Unexplained High-Risk Breast Cancer
Families |
Dr. Gopalrao Velagaleti |
UT Health - San Antonio |
Texas, USA |
Vigor and Reproducibility in Research: The Cell Line Saga: Is OGM
the Answer? |
Dr. Matthew Brian Couger |
Brigham and Women's Hospital |
Massachusetts, USA |
The Chromosomal Landscape of Mesothelioma |
Dr. Juan Diaz Martin |
Instituto de Biomedicina de Sevilla (IBiS) |
Sevilla, Spain |
Complex Rearrangement Patterns in Undifferentiated Small Round Cell
Sarcomas Associated with Poor Outcomes in Clinical Research |
Dr. Ravindra Kolhe |
Medical College of Georgia at Augusta University |
Georgia, USA |
Utility of Optical Genome Mapping for the Chromosomal
Characterization of Solid Tumors |
January 13: OGM + NGS |
|
|
Speaker Name |
Institution |
|
Talk Title |
Dr. Kornelia Neveling |
Radboud University Medical Center |
Nijmegen, Netherlands |
Optical Genome Mapping: Different Types of Hidden SV's in Families
with Inherited Retinal Diseases |
Dr. Mariangela Sabatella |
Princess Máxima Center for Pediatric Oncology |
Utrecht, Netherlands |
Enlightening the Dark Matter of the Genome: OGM Identifies a
Germline Retrotransposon Insertion in SMARCB1 in Two Siblings with
Atypical Teratoid Rhabdoid Tumors |
Dr. Gordana Raca |
Children's Hospital Los Angeles |
California, USA |
OGM and Capture-Based RNA-Seq Enable Comprehensive Genomic
Characterization of Pediatric B-lymphoblastic Leukemias |
Arran Constantine |
bit.bio |
Cambridge, UK |
Cytogenetic QC at bit.bio: How a Next-Generation Cytogenetics
Platform Enhances Quality Control of Next-Generation Cells |
Dr. Saumyaa Saumyaa |
AstraZeneca |
Cambridge, UK |
Detection and Characterization of On- and Off-target Integration of
Foreign DNA in the Host Genomes, for Therapeutic Cell and Gene
Therapy Development, Using OGM |
Dr. Laila El-Khattabi |
Assistance Publique–Hôpitaux de Paris (AP-HP) - Université de
Paris |
Paris, France |
Molecular Characterization of Genome Structural Variants in
Developmental Disorders: Comparison Between OGM and Short Read
WGS |
Dr. Jens Luebeck |
University of California, San Diego |
California, USA |
Combined NGS and OGM Reveal the Complex Structures of Circular
Extrachromosomal DNA and other Focal Amplifications in Cancer
Genomes |
Dr. Ravindra Kolhe |
Medical College of Georgia at Augusta University |
Georgia, USA |
Clinical Utility of Combined Optical Genome Mapping and
Comprehensive Genomic Sequencing in Robust Evaluation of
Hematological Cancers |
Dr. Rashmi Kanagal Shamana |
MD Anderson Cancer Center |
Texas, USA |
A Comprehensive Assessment of a Large MDS Cohort at MD Anderson
Cancer Center Using Optical Genome Mapping and a Targeted NGS
Panel |
Symposium registration is open to all and there is no charge for
attending this event. Register today at
https://www.labroots.com/ms/virtual-event/bngo2022
About Bionano Genomics
Bionano is a provider of genome analysis solutions that can
enable researchers and clinicians to reveal answers to challenging
questions in biology and medicine. The Company’s mission is to
transform the way the world sees the genome through OGM solutions,
diagnostic services and software. The Company offers OGM solutions
for applications across basic, translational and clinical research.
Through its Lineagen business, the Company also provides diagnostic
testing for patients with clinical presentations consistent with
autism spectrum disorder and other neurodevelopmental disabilities.
Through its BioDiscovery business, the Company also offers an
industry-leading, platform-agnostic software solution, which
integrates next-generation sequencing and microarray data designed
to provide analysis, visualization, interpretation and reporting of
copy number variants, single-nucleotide variants and absence of
heterozygosity across the genome in one consolidated view. For more
information, visit www.bionanogenomics.com, www.lineagen.com or
www.biodiscovery.com
Forward-Looking Statements of Bionano
Genomics
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,”
“estimate,” “intend” and similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances) convey uncertainty of future events or outcomes and
are intended to identify these forward-looking statements.
Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things, the anticipated
benefits of the Symposium, our plans to conduct a Symposium in
China later this year, and the potential for OGM to become the
standard of care. Each of these forward-looking statements involves
risks and uncertainties. Actual results or developments may differ
materially from those projected or implied in these forward-looking
statements. Factors that may cause such a difference include the
risks and uncertainties associated with: the impact of the COVID-19
pandemic on our business and the global economy; general market
conditions; changes in the competitive landscape, including the
introduction of competitive technologies or improvements in
existing technologies; failure of future study results to support
those demonstrated during the presentations referenced in this
press release; changes in our strategic and commercial plans; our
ability to obtain sufficient financing to fund our strategic plans
and commercialization efforts; the ability of medical and research
institutions to obtain funding to support adoption or continued use
of our technologies; and the risks and uncertainties associated
with our business and financial condition in general,
including the risks and uncertainties described in our filings with
the Securities and Exchange Commission, including, without
limitation, our Annual Report on Form 10-K for the year ended
December 31, 2020 and in other filings subsequently made by us with
the Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made and are based on management’s
assumptions and estimates as of such date. We do not undertake any
obligation to publicly update any forward-looking statements,
whether as a result of the receipt of new information, the
occurrence of future events or otherwise.
CONTACTSCompany Contact:Erik Holmlin, CEOBionano Genomics,
Inc.+1 (858) 888-7610eholmlin@bionanogenomics.com
Investor Relations:Amy ConradJuniper Point+1 (858)
366-3243amy@juniper-point.com
Media Relations:Michael SullivanSeismic+1 (503)
799-7520michael@teamseismic.com
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Apr 2023 to Apr 2024